XML 25 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statement of Convertible Preferred Stock and Stockholders’ Equity - 11 months ended Dec. 31, 2024 - USD ($)
$ in Thousands
Convertible Preferred Stock
Series A
Convertible Preferred Stock
Series A Non-Voting
Convertible Preferred Stock
Series B Non-Voting
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Series A
 [1]
Total
Balances at Feb. 05, 2024 $ 3 $ (2)   $ 1
Balances (in Shares) at Feb. 05, 2024 3,197,975          
Issuance of common stock $ 2 (2)  
Issuance of common stock (in Shares) 2,207,553          
Issuance of Series A convertible preferred stock, net of issuance costs of $69 $ 2,931  
Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares) 20,000,000          
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization $ (2,931) $ 2,931   2,931
Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization (in Shares) (20,000,000) 137,138          
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization $ 3 26,445   26,448
Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares) 2,722,207          
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing $ 20 248,437   248,457
Issuance of common stock and pre-funded warrants in the Pre-Closing Financing (in Shares) 20,061,932          
Issuance costs of Pre-Closing Financing and reverse recapitalization (20,504)   (20,504)
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization $ 1 4,999   5,000
Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization (in Shares) 1,208,883          
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing $ 56,097 $ 6 144,433   144,439
Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares) 2,439 5,600,000          
Issuance costs of PIPE Financing $ (3,263) (8,592)   (8,592)
Conversion of Series A non-voting convertible preferred stock to common stock $ (52,834) $ 2 52,832   52,834
Conversion of Series A non-voting convertible preferred stock to common stock (in Shares) (2,439) 2,439,000          
Issuance of common stock under employee stock purchase plan 53   53
Issuance of common stock under employee stock purchase plan (in Shares) 2,960          
Reclassification of the Paruka warrant from liability to equity 10,357   10,357
Stock-based compensation expense 4,562   4,562
Unrealized loss on marketable securities (41)   (41)
Net loss (65,037) (83,724) $ (1,918) (83,724)
Balances at Dec. 31, 2024 $ 2,931 $ 37 $ 463,018 $ (41) $ (83,724)   $ 382,221
Balances (in Shares) at Dec. 31, 2024 137,138 37,440,510          
[1] The weighted-average number of shares of as-converted Company Series A Preferred Stock used in the loss allocation was 495,191 for the period from February 6, 2024 (inception) to December 31, 2024.